Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SHP2 is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene. It plays a crucial role in various cell signaling pathways, including RAS/MAPK, PI3K/AKT, and JAK/STAT, regulating cell growth, proliferation, and differentiation. SHP2 consists of two SH2 domains (N-SH2 and C-SH2), a PTP catalytic domain, and a C-terminal tail. Its activity is regulated by auto-inhibition, where the N-SH2 domain blocks the PTP active site. Binding of phosphorylated ligands to the N-SH2 relieves this inhibition, activating SHP2. Mutations in PTPN11/SHP2 are implicated in several diseases, including Noonan syndrome, LEOPARD syndrome, hematologic malignancies, and solid tumors. Due to its central role in cancer-related signaling, SHP2 has emerged as an important drug target, with inhibitors targeting allosteric sites under development for cancer therapy.
Allosteric inhibition of SHP2
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Src Homology Phosphotyrosyl Phosphatase 2 (SHP2).